Screening for cervical cancer with the human papillomavirus test in an area of central Italy with no previous active cytological screening programme

Journal of Medical Screening

Volumn 17, Issue 2, 2010, Pages 79-86

  Confortini, Massimo ^a   Rossi, Paolo Giorgi ^b   Barbarino, Paolo ^c   Passarelli, Anna Maria ^d   Orzella, Letizia ^b   Tufi, Maria Concetta ^c  

^a ISPO   (Italy)

^b Agency for Public Health   (Italy)

^c UOC Screening e Prevenzione ASL Roma G   (Italy)

^d ASL Roma G   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; FEMALE; HUMAN; ISOLATION AND PURIFICATION; ITALY; MASS SCREENING; METHODOLOGY; MIDDLE AGED; PAPILLOMA VIRUS; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

ADULT; FEMALE; HUMANS; ITALY; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 77954938820     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: 10.1258/jms.2010.009092     Document Type: Article

References (38)

1. World Health Organization, International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Human Papillomaviruses. Vol.90. Lyon: IARC, 2007
2. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-1101
3. Ronco G, Segnan N, Giorgi-Rossi P, et al., New Technologies for Cervical Cancer Working Group. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006;98:765-774 (Pubitemid 43983300)
4. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006;24(Suppl. 3):S3-78-89
5. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004;96:280-293 (Pubitemid 38256273)
6. Ronco G, Cuzick J, Segnan N, et al., the NTCC Working Group. HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. Eur J Cancer 2007;43:476-480
7. Solomon D, Schiffman M, Tarone R, ALTS Study group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-299 (Pubitemid 32219816)
8. Bulkmans NW, Rozendaal L, Snijders PJ, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004;110:94-101
9. Ronco G, Giorgi-Rossi P, Carozzi F, et al., New Technologies for Cervical Cancer screening Working Group. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006;7:547-555
10. Naucler P, Ryd W, Törnberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589-1597
11. Ronco G, Giorgi-Rossi P, Carozzi F, et al., New Technologies for Cervical Cancer Screening Working Group. Results: at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008;100:492-501
12. Cuzick J, Mayrand MH, Ronco G, Snijders P, Wardle J. Chapter 10: new dimensions in cervical cancer screening. Vaccine 2006;24(Suppl. 3): S3/90-7
13. Franco EL, Cuzick J, Hildesheim A, de Sanjosé S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006;24(Suppl. 3):S3/171-7
14. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-1772
15. Arbyn M, Anttila A, Jordan J, et al., eds. European Guidelines for Quality Assurance on Cervical Cancer Screening. 2nd edn. Brussels: European Community. Luxembourg: Office for Official Publications of the European Communities, 2008
16. Ronco G, Giorgi Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing on the subsequent detection of cervical invasive and intraepithelial neoplasia:results from a randomised controlled trial. Lancet Oncol 2010;11:249-257
17. IARC Working Group on the Evaluation of Cancer Preventive Strategies. Cervix Cancer Screening. IARC Handbooks of Cancer Prevention No. 10. Lyon: IARC, 2005
18. Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 2000;92:818-825
19. Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000;283:87-93
20. Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001;84:1616-1623
21. Petry KU, Menton S, Menton M, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003;88:1570-1577
22. Demografia in cifre. ISTAT, See http://demo.istat.it/ (last checked 16 February 2010)
23. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-2119
24. Ronco G, Giubilato P, Naldoni C, et al. Extension of organised cervical cancer screening programmes in Italy and their process indicators. Epidemiol Prev 2008;32(Suppl. 1):37-54
25. Arbyn M, Ronco G, Meijer CJ, Naucler P. Trials comparing cytology with human papillomavirus screening. Lancet Oncol 2009;10:935-936
26. Ronco G, van Ballegooijen M, Becker N, et al. Process performance of cervical screening programmes in Europe. Eur J Cancer 2009;45:2659-2670
27. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002;288:1749-1757
28. Mandelblatt JS, Lawrence WF, Womack SM, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002;287:2372-2381
29. Maxwell GL, Carlson JW, Ochoa M, Krivak T, Rose GS, Myers ER. Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries. Obstet Gynecol 2002;100:740-748
30. Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004;103:619-631
31. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al., Alliance for Cervical Cancer Prevention Cost Working Group. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005;353:2158-2168
32. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst 2005;97:888-895
33. Holmes J, Hemmett L, Garfield S. The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies. Eur J Health Econ 2005;6:30-37
34. Ronco G, Pilutti S, Patriarca S, et al., Turin Cervical Screening Working Group. Impact of the introduction of organised screening for cervical cancer in Turin, Italy: cancer incidence by screening history 1992-1998. Br J Cancer 2005;93:376-378
35. Ciatto S, Grazzini G, Cecchini S, Iossa A. Screening history of incident cases of invasive carcinoma of the cervix. Florence district 1988-1989. Tumori 1993;79:311-313
36. Kulasingam SL, Kim JJ, Lawrence WF, et al., ALTS Group. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst 2006;98:92-100
37. Melnikow J, Birch S. Human papillomavirus triage of atypical squamous cells of undetermined significance: cost-effective, but at what cost? J Natl Cancer Inst 2006;98:82-83
38. Giorgi Rossi P, Segnan N, Zappa M, et al., the NTCC Working Group. The impact of new technologies in cervical cancer screening: results of the recruitment phase of a large randomised controlled trial from a public health perspective. Int J Cancer 2007;121: 2729-2734 (Pubitemid 350136419)